Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Classical hematology 13Plasma cell 3Gastrointestinal 3Tumor-Agnostic 2Thoracic 2Genitourinary 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1CNS 1Breast 1

Conditions

Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery 1

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rivaroxaban × Gynecologic × Clear all
NCT06220123 2025-07-22

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Beijing Suncadia Pharmaceuticals Co., Ltd

Phase 2 Completed
225 enrolled
Classical hematologyGynecologic

Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Data powered by HemOnc (CC BY 4.0) Colophon âš¡